Trials / Completed
CompletedNCT01608243
Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts
Investigation of the Safety, Tolerability and Pharmacodynamic Effects of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts in Adults With House Dust Mite-associated Allergic Asthma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 94 (actual)
- Sponsor
- Stallergenes Greer · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the safety of different doses of sublingual tablets of house dust mite allergen extracts in adults with house dust mite-associated allergic asthma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | SLIT tablets of house dust mite allergen extracts | 10 dosing days |
| BIOLOGICAL | Matching placebo | 10 dosing days |
Timeline
- Start date
- 2012-05-01
- Primary completion
- 2014-06-01
- Completion
- 2014-06-01
- First posted
- 2012-05-31
- Last updated
- 2014-07-01
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT01608243. Inclusion in this directory is not an endorsement.